Related Experiment Videos
Daptomycin - a novel antibiotic against Gram-positive pathogens
Kerry L LaPlante1, Michael J Rybak
1University of Rhode Island, Department of Pharmacy Practice, Kingston, RI 02881, USA. KerryTedesco@uri.edu
Expert Opinion on Pharmacotherapy
|October 27, 2004
Summary
Daptomycin offers a new treatment for resistant Gram-positive infections, including MRSA. This antibiotic is vital as resistance to traditional drugs like vancomycin grows, highlighting the need for novel antimicrobial agents.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Increasing prevalence of resistant Gram-positive bacterial infections, particularly Staphylococcus aureus.
- Limited treatment options for infections caused by multi-drug resistant organisms.
- Rising resistance to established antibiotics such as penicillin, cephalosporins, and vancomycin.
Purpose of the Study:
- To introduce daptomycin as a novel antimicrobial agent.
- To discuss its role in treating resistant Gram-positive infections.
- To address the unmet need for new antibiotics against multi-drug resistant pathogens.
Main Methods:
- Review of daptomycin's properties and approved indications.
- Analysis of common causative organisms in skin and skin-structure infections.
- Examination of antibiotic resistance trends, including methicillin-resistant Staphylococcus aureus (MRSA).
Main Results:
- Daptomycin is approved for complicated skin and skin-structure infections.
- Common pathogens include Staphylococcus aureus and various streptococci.
- Methicillin-resistant Staphylococcus aureus (MRSA) constitutes a significant portion of infections, with emerging vancomycin resistance.
Conclusions:
- Daptomycin represents a new class of antibiotics effective against resistant Gram-positive bacteria.
- There is an ongoing and critical need for novel antibiotics to combat the growing threat of multi-drug resistant infections.